Bioventix PLC

LSE BVXP.L

Bioventix PLC EBITDA Margin for the year ending June 30, 2024: 78.93%

Bioventix PLC EBITDA Margin is 78.93% for the year ending June 30, 2024, a -0.81% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

Bioventix PLC EBITDA Margin for the year ending June 30, 2023 was 79.58%, a 0.02% change year over year.
Bioventix PLC EBITDA Margin for the year ending June 30, 2022 was 79.56%, a 5.79% change year over year.
Bioventix PLC EBITDA Margin for the year ending June 30, 2021 was 75.21%, a -4.42% change year over year.
Bioventix PLC EBITDA Margin for the year ending June 30, 2020 was 78.68%, a 2.98% change year over year.

Key data

Date	EBITDA Margin	EBIT Margin	Depreciation and Amortization	EBIT

LSE: BVXP.L

Bioventix PLC

CEO	Mr. Peter John Harrison MA
IPO Date	April 29, 2014
Location	United Kingdom
Headquarters	27–28 Eastcastle Street
Employees	12
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, infectious disease, oncology, and miscellaneous indications. It also provides contract SMAs and recombinant services. Bioventix PLC was incorporated in 2003 and is based in London, the United Kingdom.

Key trends

Past 5 years